Liminal BioSciences Inc.
LMNL · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.00 | 0.00 | -0.00 |
| FCF Yield | -8,551.43% | -8,584.57% | -1,720.10% | -1,128.78% |
| EV / EBITDA | 1.11 | 1.03 | -0.32 | 0.02 |
| Quality | ||||
| ROIC | -78.82% | -43.19% | -93.23% | -147.88% |
| Gross Margin | 100.00% | 100.00% | 38.71% | 43.66% |
| Cash Conversion Ratio | -51.16 | -8.16 | 0.64 | 0.48 |
| Growth | ||||
| Revenue 3-Year CAGR | -50.55% | -49.20% | -58.78% | -49.95% |
| Free Cash Flow Growth | 68.18% | -28.35% | 24.92% | -18.56% |
| Safety | ||||
| Net Debt / EBITDA | 1.12 | 1.06 | -0.27 | 0.07 |
| Interest Coverage | -30.59 | -7.83 | -10.81 | -14.99 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.22 | 0.37 |
| Cash Conversion Cycle | 1,071.33 | 606.25 | 469.70 | 598.35 |